HC Wainwright Issues Positive Forecast for KYMR Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Research analysts at HC Wainwright increased their Q2 2026 earnings per share estimates for shares of Kymera Therapeutics in a research report issued on Monday, May 4th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.68) for the quarter, up from their prior estimate of ($0.74). The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($3.35) per share. HC Wainwright also issued estimates for Kymera Therapeutics’ Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.76) EPS, FY2027 earnings at ($3.21) EPS, FY2028 earnings at ($3.30) EPS, FY2029 earnings at ($2.65) EPS and FY2030 earnings at $1.07 EPS.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The business had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.82) earnings per share.

Other analysts also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. Royal Bank Of Canada restated an “outperform” rating and set a $108.00 target price on shares of Kymera Therapeutics in a report on Thursday, February 26th. Barclays upped their price target on Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research report on Tuesday, January 27th. UBS Group lifted their price objective on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Finally, Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $118.70.

Kymera Therapeutics Trading Down 1.1%

KYMR opened at $82.71 on Wednesday. The firm has a market capitalization of $6.80 billion, a PE ratio of -23.17 and a beta of 2.06. Kymera Therapeutics has a twelve month low of $28.06 and a twelve month high of $103.00. The firm’s 50-day moving average price is $84.42 and its 200 day moving average price is $76.61.

Insider Buying and Selling

In other news, CFO Bruce N. Jacobs sold 7,576 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $88.93, for a total transaction of $673,733.68. Following the sale, the chief financial officer owned 237,483 shares of the company’s stock, valued at approximately $21,119,363.19. The trade was a 3.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bruce Booth sold 81,866 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $90.13, for a total value of $7,378,582.58. Following the completion of the transaction, the director owned 675,341 shares in the company, valued at $60,868,484.33. This represents a 10.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 380,734 shares of company stock worth $32,193,902 over the last ninety days. 16.01% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Kymera Therapeutics by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after purchasing an additional 1,833 shares during the period. Millennium Management LLC boosted its position in shares of Kymera Therapeutics by 340.4% during the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after buying an additional 394,562 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after buying an additional 491,737 shares in the last quarter. Invesco Ltd. grew its stake in shares of Kymera Therapeutics by 13.8% in the second quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock valued at $2,090,000 after buying an additional 5,809 shares in the last quarter. Finally, Sei Investments Co. purchased a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at $265,000.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera presented new preclinical data showing KT‑579 (oral IRF5 degrader) produced activity comparable or superior to approved/clinically active therapies in IBD models — a meaningful R&D positive if confirmed in clinical studies. Article Title
• Positive Sentiment: Management will participate in multiple May investor conferences (fireside chats), increasing visibility with investors and analysts — typically supportive for sentiment and liquidity. Article Title
• Positive Sentiment: Q1 results and the accompanying presentation prompted analysts to lift estimates in some reports and coverage; positive analyst reaction to quarterly revenue and beats can support the stock. Article Title
• Neutral Sentiment: Kymera published its Q1 earnings presentation (details on pipeline progress, financials and guidance assumptions), useful for investors but not an immediate catalyst by itself. Article Title
• Neutral Sentiment: Company celebrated its 10‑year anniversary and rang the Nasdaq opening bell — PR/branding event with limited direct impact on valuation. Article Title
• Negative Sentiment: Brookline Capital Markets issued multiple model changes: they raised some near‑ and long‑term estimates (e.g., FY2026, FY2028–FY2030) but lowered Q3/Q4 2026 and FY2027 forecasts — the mixed/downgrade elements could weigh on sentiment by signaling slower expected progress or higher near‑term spend. Article Title

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.